Forty‐eight out of 54 (88.9%) ECs scoring ≥ 3 points had a recurrent POLE mutation (including hotspot mutations), compared with 7/28 (25%) tumours scoring ≤ 2 points (p ≤ 0.001, χ2 statistics). This evidence concerns the gene POLE and neoplasm.